TWO PEPTIDES WITH POTENT ANTI-HERPES ACTIVITY IN VITRO, MCP-1 AND MCP-2, HAVE BEEN ISOLATED FROM RABBIT MACROPHAGES.

Award Information
Agency:
Department of Health and Human Services
Amount:
$50,000.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1985
Phase:
Phase I
Agency Tracking Number:
2906
Solicitation Topic Code:
N/A
Small Business Information
California Biotechnology Inc
2450 Bayshore Frontage Road, Mountain View, CA, 94043
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 KAREN TALMADGE
 PRINCIPAL INVESTIGATOR
 (415) 966-1550
Business Contact
Phone: () -
Research Institution
N/A
Abstract
TWO PEPTIDES WITH POTENT ANTI-HERPES ACTIVITY IN VITRO, MCP-1 AND MCP-2, HAVE BEEN ISOLATED FROM RABBIT MACROPHAGES. THE LONG-TERM OBJECTIVE OF THIS APPLICATION IS THE DEVELOPMENT OF THESE PEPTIDES FOR HUMAN THERAPEUTIC USE. BECAUSE THE NATURAL SOURCE IS LIMITED, RECOMBINANT DNA TECHNIQUES WILL BE USED TO PRODUCE THESE PEPTIDES FOR TESTING IN VARIOUS ANIMAL MODELS OF HERPETIC DISEASE. SPECIFIC AIMS INCLUDE: 1.CHEMICALLY CLEAVING AND ISOLATING BIOLOGICALLY ACTIVE MCP-1 FROM A FUSION PROTEIN EXPRESSED IN ESCHERICHIA COLI; 2.EXPRESSING A FUSION PROTEIN IN E. COLI CONTAINING 3.SECRETING MCP-1 INTO THE E. COLI PERIPLASM TO TEST FOR STABLE, DIRECT MCP-1 EXPRESSION. 1.METHODS WILL BE IN PLACE FOR THE PURIFICATION OF BIOLOGICALLY ACTIVE MCP-1 FROM BACTERIA; 2.ENOUGH PEPTIDE WILL BE ISOLATED TO INITIATE ANIMAL STUDIES; 3.THE MULTIPLE MCP-1 GENE AND SECRETION GENE CONSTRUCTS WILL BE BUILT. PHASE II WILL INCLUDE: 1.ANIMAL STUDIES OF MCP-1 IN VIVO ANTI-HERPES EFFICACY;

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government